What is Xylanaest 0,5 % mit Epinephrin 1:2000.000?
Numbing the skin before you have certain medical procedures (eg, injections, minor skin surgery) in the treated area.
Xylanaest 0,5 % mit Epinephrin 1:2000.000 iontophoretic patch is a local anesthetic. It works by stopping nerves from transmitting painful impulses to the brain.
Xylanaest 0,5 % mit Epinephrin 1:2000.000 indications
Production of local or regional anaesth by infiltration techniques; IV regional anaesth, by peripheral nerve block techniques eg intercostal blocks; major plexus blocks eg brachial plexus blocks & by epidural & subarachnoid blocks. As Spray: Surface anaesth: In dentistry Otorhinolaryngology for maxillary sinus Paracentesis During delivery Introduction of instruments & catheters into the resp & digestive tract Laryngeal & tracheal procedures As Gel: As a surface anaesth & lubricant for the male & female urethra during cystoscopy, catheterisation, exploration by sound & other endourethral procedures, nasal & pharyngeal cavities in endoscopic procedures eg gastroscopy & bronchoscopy, during proctoscopy & rectoscopy & tracheal intubation. Symptomatic treatment of pain in connection w/ cystitis & urethritis. As Rectal Cream or suppositories for hemorrhoids
How should I use Xylanaest 0,5 % mit Epinephrin 1:2000.000?
Use Xylanaest 0,5 % mit Epinephrin 1:2000.000 iontophoretic patch as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Xylanaest 0,5 % mit Epinephrin 1:2000.000 iontophoretic patch is usually applied at your doctor's office, hospital, or clinic. If you will be using Xylanaest 0,5 % mit Epinephrin 1:2000.000 iontophoretic patch at home, a health care provider will teach you how to use it. Be sure you understand how to use Xylanaest 0,5 % mit Epinephrin 1:2000.000 iontophoretic patch. Follow the procedures you are taught when you use a dose. Contact your health care provider if you have any questions.
- Xylanaest 0,5 % mit Epinephrin 1:2000.000 iontophoretic patch is only to be used on intact, clean, dry skin, Do not apply Xylanaest 0,5 % mit Epinephrin 1:2000.000 iontophoretic patch to broken, damaged, inflamed, or hairy skin.
- If you miss a dose of Xylanaest 0,5 % mit Epinephrin 1:2000.000 iontophoretic patch, contact your doctor right away.
Ask your health care provider any questions you may have about how to use Xylanaest 0,5 % mit Epinephrin 1:2000.000 iontophoretic patch.
Xylanaest 0,5 % mit Epinephrin 1:2000.000 description
Xylanaest 0,5 % mit Epinephrin 1:2000.000/ Adrenaline is sterile, isotonic, and in addition, contains adrenaline acid tartrate and sodium metabisulfite 0.5 mg/mL as antioxidant. It contains no antimicrobial agent and should be used only once and any residue be discarded.
Xylanaest 0,5 % mit Epinephrin 1:2000.000/ Adrenaline has a pH of approximately 3-4.5.
The chemical abstracts service (CAS) number for lignocaine HCl [Australian approved name (AAN)], is 6108-05-0 and anhydrous lignocaine HCl is 73-78-9. The chemical name for lignocaine HCl is 2-Diethylaminoaceto-2'6'-xylidide HCl. The CAS number for adrenaline is 51-43-4. The chemical name for adrenaline is (R)-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol. The AAN is adrenaline.
Lignocaine base has a pKa of 7.85 (25°C), an oil/water coefficient of 2.9 and a molecular weight of 234.3.
Lignocaine is classed as a membrane-stabilising agent and is a local anaesthetic of the amide-type. It is extremely stable.
Xylanaest 0,5 % mit Epinephrin 1:2000.000 dosage
The lowest dosage and volume that results in effective anaesthesia should be used and should be based on the status of the patient and the type of regional anaesthesia intended. Xylanaest 0,5 % mit Epinephrin 1:2000.000/ Adrenaline contains no antimicrobial agent and should be used only once and any residue discarded.
Lignocaine should be administered with great caution to patients with impaired cardiovascular function as they may be less able to compensate for functional changes associated with the prolongation of AV conduction produced by these drugs.
Adults: See table.
Recommended Doses: The previously suggested concentrations and volumes serve only as a guide. Toxic doses vary widely between patients and toxic effects may occur after any local anaesthetic procedure.
Careful observation of the patient must therefore be maintained. It is recommended that the dose of lignocaine at any one time should not exceed 7 mg/kg. However, the dose administered must be tailored to the individual patient and procedure, and the maximum doses here quoted should be used as a guide only.
Hypotension: During thoracic, lumbar and caudal epidural anaesthesia, a marked fall in blood pressure and/or intercostal paralysis may be seen, possibly due to the use of excessive doses, improper positioning of the patient or accidental disposition of the anaesthetic within the subarachnoid space. Hypotension and bradycardia may occur as a result of sympathetic blockade.
Test Dose: For epidural anaesthesia, a 3-5 mL test dose of a local anaesthetic solution preferably containing up to 15 mcg of adrenaline (eg, 3 mL of Xylocaine 2% with adrenaline 1:200,000) should be administered.
Verbal contact and repeated monitoring of heart rate and blood pressure should be maintained for 5 min after the test dose, after which, in the absence of signs of subarachnoid or intravascular injection, the main dose may be administered.
Use of a test dose containing adrenaline may have further advantages in that an intravascular injection of adrenaline will be quickly recognised by an increase in heart rate, usually within about 40 sec. To detect this, the heart rate and rhythm should be monitored with an electrocardiogram.
Prior to administration of the total dose, aspiration should be repeated. The main dose should be injected slowly, with continual assessment of the patient. If toxic symptoms or signs occur, the injection should be stopped immediately.
Children: A reduced dosage based on bodyweight or surface area should be used. The dosage should be calculated for each patient individually and modified in accordance with the physician's experience and knowledge of the patient.
In order to minimise the possibility of toxic effects, the use of Xylocaine 0.5% or 1% solutions is recommended for most anaesthetic procedures involving paediatric patients.
In children, early signs of local anaesthetic toxicity may be difficult to detect in cases where the block is given during general anaesthesia.
Elderly: A reduction in dosage may be necessary for elderly patients especially those with compromised cardiovascular and/or hepatic function.
In epidural anaesthesia, a smaller dose may provide adequate anaesthesia.
Impaired Hepatic Function: Although lignocaine is metabolised by the liver, dosage reduction for local anaesthesia is probably not warranted. However, caution should be exercised with repeated doses.
Impaired Renal Function: Impairment of renal function is unlikely to affect lignocaine clearance in the short-term (24 hrs). However, toxicity due to accumulation may develop with prolonged or repeated administration.
Xylanaest 0,5 % mit Epinephrin 1:2000.000 interactions
Xylanaest 0,5 % mit Epinephrin 1:2000.000 should be used cautiously in patients with hyperthyroidism, hypertension and cardiac arrhythmias. All vasopressors should be used cautiously in patients taking monoamine oxidase (MAO) inhibitors.
Xylanaest 0,5 % mit Epinephrin 1:2000.000 should not be administered concomitantly with other sympathomimetic drugs (such as isoproterenol) because of possible additive effects and increased toxicity.
Combined effects may induce serious cardiac arrhythmias. They may be administered alternately when the preceding effect of other such drug has subsided.
Administration of Xylanaest 0,5 % mit Epinephrin 1:2000.000 to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia.. When encountered, such arrhythmias may respond to administration of a beta-adrenergic blocking drug. Xylanaest 0,5 % mit Epinephrin 1:2000.000 also should be used cautiously with other drugs (e.g., digitalis, glycosides) that sensitize the myocardium to the actions of sympathomimetic drugs.
Diuretic agents may decrease vascular response to pressor drugs such as Xylanaest 0,5 % mit Epinephrin 1:2000.000.
Xylanaest 0,5 % mit Epinephrin 1:2000.000 may antagonize the neuron blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter.
Xylanaest 0,5 % mit Epinephrin 1:2000.000 side effects
See also:
What are the possible side effects of Xylanaest 0,5 % mit Epinephrin 1:2000.000?
Get emergency medical help if you have any of these signs of an allergic reaction to lorazepam: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Call your doctor at once if you have any of these serious side effects:
confusion, depressed mood, thoughts of suicide or hurting yourself;
hyperactivity, agitation, hostility;
hallucinations; or
feeling light-headed, fainting.
Less serious lorazepam side effects may include:
drowsiness, dizziness, tiredness;
blurred vision;
sleep problems (insomnia);
muscle weakness, lack of balance or coordination;
amnesia or forgetfulness, trouble concentrating;
nausea, vomiting, constipation;
appetite changes; or
skin rash.
Xylanaest 0,5 % mit Epinephrin 1:2000.000 contraindications
Allergy or hypersensitivity to amide-type local anaesthetics, sodium metabisulfite or to any excipients of Xylanaest 0,5 % mit Epinephrin 1:2000.000/ Adrenaline. Detection of suspected hypersensitivity by skin testing is of limited value.
Local anaesthetics are contraindicated for epidural and spinal anaesthesia in patients with uncorrected hypotension or coagulation disorders or in patients receiving anticoagulation treatment.
Local anaesthetic techniques must not be used when there is inflammation and/or sepsis in the region of the proposed injection and/or in the presence of septicaemia.
General contraindications related to epidural anaesthesia, regardless of the local anaesthetic used, should be taken into account.
Adrenaline is contraindicated in conditions where the production or exacerbation of tachycardia may prove fatal eg, thyrotoxicosis or severe heart disease, or in obstetrics when maternal blood pressure exceeds 130/80 mmHg.
Solutions with adrenaline must not be used for local analgesia in parts of the body with compromised blood supply or supplied by end arteries eg, fingers, toes, nose, ears or penis. There is a possibility of producing arterial vasoconstriction and subsequent ischaemic gangrene distal to the site of injection.
Solutions with adrenaline must not be used for IV regional techniques.
Solutions with adrenaline should not be used in patients with known sensitivity to sympathomimetic amines.
Solutions with adrenaline should not be used in most patients with cerebral arteriosclerosis.
Active ingredient matches for Xylanaest 0,5 % mit Epinephrin 1:2000.000:
Epinephrine/Lidocaine in Austria.
List of Xylanaest 0,5 % mit Epinephrin 1:2000.000 substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Xylanaest mit Epinephrin (Austria) | |
| Xylestesin A (Hong Kong, Japan, Lithuania, New Zealand) | |
| Xylocain 2%DENTAL mit Adrenalin 1:100 000 (Germany) | |
| Xylocain Adrenalin (Denmark, Finland, Iceland, Norway, Sweden) | |
| Xylocain Dental adrenalin (Finland, Iceland, Norway) | |
| Xylocain mit Adrenalin (Germany) | |
| Xylocaina 1% con Epinefrina (Argentina) | |
| Xylocaina 2% con Epinefrina (Argentina) | |
| Xylocaina con Epinefrina (Argentina) | |
| Xylocaina EV (Mexico) | |
| Xylocaine 0.5% (Japan) | |
| Xylocaine 0.5% liquid 5 mg (Astrazeneca Canada Inc (Canada)) | |
| Xylocaine 0.5% solution 5 mg (Astrazeneca Canada Inc (Canada)) | |
| Xylocaine 0.5% with Adrenaline 1:200,000 | |
| Injectable; Injection; Lidocaine Hydrochloride 5 mg; Epinephrine Hydrogen Tartrate 9.1 mcg / ml | |
| Xylocaine 0.5% with Epinephrine 1:100,000 | |
| Injectable; Injection; Epinephrine 0.01 mg; Lidocaine Hydrochloride 5 mg / ml | |
| Xylocaine 0.5% with Epinephrine 1:200,000 | |
| Injectable; Injection; Epinephrine 0.005 mg; Lidocaine Hydrochloride 5 mg / ml | |
| Xylocaine 1% (Japan) | |
| Xylocaine 1% liquid 10 mg (Astrazeneca Canada Inc (Canada)) | |
| Xylocaine 1% with Adrenaline (United Kingdom) | |
| Injectable; Injection; Lidocaine Hydrochloride Monohydrate 1%; Epinephrine Tartrate 5 mcg / 1:200, 000 | |
| Xylocaine 1% with Adrenaline 1:100,000 | |
| Injectable; Injection; Lidocaine Hydrochloride 10 mg; Epinephrine Hydrogen Tartrate 18.2 mcg / ml | |
| Xylocaine 1% with Adrenaline 1:200,000 (Malta) | |
| Injectable; Injection; Lidocaine Hydrochloride 10 mg; Epinephrine Hydrogen Tartrate 9.1 mcg / ml | |
| Xylocaine 1% with Epinephrine 1:100000 | |
| Injectable; Injection; Epinephrine 0.01 mg; Lidocaine Hydrochloride 10 mg / ml | |
| Xylocaine 1% with Epinephrine 1:200000 | |
| Injectable; Injection; Epinephrine 0.005 mg; Lidocaine Hydrochloride 10 mg / ml | |
| Xylocaine 1.5% with Epinephrine 1:200000 | |
| Injectable; Injection; Epinephrine 0.005 mg; Lidocaine Hydrochloride 15 mg / ml | |
| Xylocaine 1.5% with Epinephrine 1:200000 Test Dose | |
| Injectable; Injection; Epinephrine 0.005 mg; Lidocaine Hydrochloride 15 mg / ml | |
| Xylocaine 2% with Adrenaline (Ireland, Malta, United Kingdom) | |
| Injectable; Injection; Lidocaine Hydrochloride Monohydrate 2%; Epinephrine Tartrate 5 mcg / 1:200, 000 | |
| Xylocaine 2% with Adrenaline 1:100,000 | |
| Injectable; Injection; Lidocaine Hydrochloride 20 mg; Epinephrine Hydrogen Tartrate 18.2 mcg / ml | |
| Xylocaine 2% with Adrenaline 1:200,000 | |
| Injectable; Injection; Lidocaine Hydrochloride 20 mg; Epinephrine Hydrogen Tartrate 9.1 mcg / ml | |
| Xylocaine 2% with Adrenaline 1:80,000 (New Zealand) | |
| Injectable; Injection; Epinephrine 0.0125 mg; Lidocaine Hydrochloride 20 mg / ml | |
| Xylocaine 2% with Epinephrine 1:100000 | |
| Injectable; Injection; Epinephrine 0.01 mg; Lidocaine Hydrochloride 20 mg / ml | |
| Xylocaine 2% with Epinephrine 1:200000 | |
| Injectable; Injection; Epinephrine 0.005 mg; Lidocaine Hydrochloride 20 mg / ml | |
| Xylocaine Adrenalin (Lithuania) | |
| Xylocaïne Adrénaline (France) | |
| Injectable; Injection; Epinephrine Tartrate 5 mcg; Lidocaine Hydrochloride Monohydrate 10 mg / ml | |
| Injectable; Injection; Epinephrine Tartrate 5 mcg; Lidocaine Hydrochloride Monohydrate 20 mg / ml | |
| XYLOCAINE ADRENALINE 2% INJECTION 1 vial / 30 ML injection each (Astra Zeneca) | $ 0.37 |
| Xylocaine Adrenaline 2% Injection (Astra Zeneca) | $ 0.01 |
| Xylocaine Adrenaline | |
| Injectable; Injection; Epinephrine Tartrate 5 mcg; Lidocaine Hydrochloride Monohydrate 10 mg / ml | |
| Injectable; Injection; Epinephrine Tartrate 5 mcg; Lidocaine Hydrochloride Monohydrate 20 mg / ml | |
| XYLOCAINE ADRENALINE 2% INJECTION 1 vial / 30 ML injection each (Astra Zeneca) | $ 0.37 |
| Xylocaine Adrenaline 2% Injection (Astra Zeneca) | $ 0.01 |
| Xylocaïne Adrénaline (France) | |
| Injectable; Injection; Epinephrine Tartrate 5 mcg; Lidocaine Hydrochloride Monohydrate 10 mg / ml | |
| Injectable; Injection; Epinephrine Tartrate 5 mcg; Lidocaine Hydrochloride Monohydrate 20 mg / ml | |
| XYLOCAINE ADRENALINE 2% INJECTION 1 vial / 30 ML injection each (Astra Zeneca) | $ 0.37 |
| Xylocaine Adrenaline 2% Injection (Astra Zeneca) | $ 0.01 |
See 287 substitutes for Xylanaest 0,5 % mit Epinephrin 1:2000.000 | |
References
- DailyMed. "LIDOCAINE; TETRACAINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- DailyMed. "EPINEPHRINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "epinephrine". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Xylanaest 0,5 % mit Epinephrin 1:2000.000 are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Xylanaest 0,5 % mit Epinephrin 1:2000.000. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
